Classical enteropathy-associated T-cell lymphoma (EATL) is an uncommon neoplasm associated with a history of childhood coeliac disease. This tumour is characterized by ulcerating intestinal masses composed of an infiltrate of medium to large cells with significant pleomorphism. They display a cytotoxic
þ and TCRb þ /À ) and are associated with features of enteropathy in the adjacent mucosa. More recently, a monomorphic form of EATL (type II EATL) has been described with a distinctive and different phenotype, namely CD3
It commonly presents as intestinal perforation or with gastrointestinal symptoms of recent onset, and is the form of EATL seen in Asia, where coeliac disease and classical EATL are almost unheard of. 3, 4 Although the expression of CD8 and CD56 is characteristic of type II EATL, a significant number lack one or the other marker (our unpublished observation), which raises diagnostic difficulties in view of the phenotypic overlap with other forms of NK-and T-cell lymphoma.
Using a commercially available antibody (Santa Cruz SC-533, Santa Cruz, CA, USA) directed against MATK/Lsk (a non-receptor tyrosine kinase) in a number of immunolabelling techniques, we examined the expression of this molecule in 22 cases of type II EATL, and in a wide variety of normal lymphoid tissues (tonsil, lymph node, Peyer's patches in the ileum and appendix) and various B-and T-cell neoplasms (see Figure 1) . In non-neoplastic cells, cytoplasmic expression of MATK is observed in B cells of the lymphoid follicles (mainly centroblasts in the dark zone), whereas nuclear localization of MATK is noted in a subset of cytotoxic CD8 þ T cells. No nuclear and only focal cytoplasmic staining (up to 20% neoplastic cells) is seen in 22 cases of diffuse large B-cell lymphoma, 30 cases of mantle cell lymphoma (MCL), 108 cases of follicular lymphoma (FL) and 25 cases of marginal zone lymphoma. Although assessment in T-cell neoplasms is somewhat complicated by accompanying reactive cytotoxic T cells, cytoplasmic staining and lack of significant nuclear expression (o40%) of MATK are seen in 15 cases of angioimmunoblastic T-cell lymphoma (AIL), 28 cases of peripheral T-cell lymphoma, NOS (PTCL, NOS), 3 cases of subcutaneous panniculitis-like T-cell lymphoma, 16 cases of alk þ anaplastic T-cell lymphoma (ALCL, alk þ ) and 6 cases of classical EATL. In contrast, high-level Letters to the Editor nuclear staining (480% of neoplastic cells) for MATK is seen in all 22 type II EATLs, including unusual cases that are CD8 À but are otherwise indistinguishable from ordinary type II EATL. More variable amount of nuclear staining (ranging from 20 to 480%) for MATK is seen in 58 cases of NK/T-cell lymphoma (NKTL).
In conclusion, we have identified a novel marker of type II EATL that shows a distinctive nuclear staining pattern in the vast majority of neoplastic cells. This marker is a useful additional tool in the diagnostic workup of this rare neoplasm, particularly in cases that lack the characteristic CD8 expression (Figure 1 ).
